Loading…
MINT-ROSUVASTATIN is a brand name for Rosuvastatin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: MINT-ROSUVASTATIN (rosuvastatin calcium tablets) is indicated in adults as an adjunct to diet, at least equivalent to the Adult Treatment Panel III (ATP III TLC diet), for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C; in…
Verbatim from this product's HC label. Tap a section to expand.
2 Breast-feeding 03/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................................
2 TABLE OF CONTENTS .......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................................
4 1 INDICATIONS ......................................................................................................................... 1 Pediatrics ...............................................................................................................................
2 Geriatrics ............................................................................................................................... 4 2 CONTRAINDICATIONS ............................................................................................................
5 4 DOSAGE AND ADMINISTRATION ............................................................................................ 1 Dosing Considerations ..........................................................................................................
2 Recommended Dose and Dosage Adjustment ..................................................................... 4 Administration ......................................................................................................................
5 Missed Dose .......................................................................................................................... 8 5 OVERDOSAGE ........................................................................................................................
8
).
Lipoprotein(a):
In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in the Lipoprotein(a) [Lp(a)] concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.
It is thus desirable to maintain and reinforce lifestyle changes in high-risk patients placed on rosuvastatin therapy.
Genetic Polymorphism:
In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure (see
2 Breast-feeding 03/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................................
2 TABLE OF CONTENTS .......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................................
4 1 INDICATIONS ......................................................................................................................... 1 Pediatrics ...............................................................................................................................
2 Geriatrics ............................................................................................................................... 4 2 CONTRAINDICATIONS ............................................................................................................
5 4 DOSAGE AND ADMINISTRATION ............................................................................................ 1 Dosing Considerations ..........................................................................................................
2 Recommended Dose and Dosage Adjustment ..................................................................... 4 Administration ......................................................................................................................
5 Missed Dose .......................................................................................................................... 8 5 OVERDOSAGE ........................................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Rosuvastatin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............................................. 8 7 WARNINGS AND PRECAUTIONS .............................................................................................. 1 Special Populations .............................................................................................................
1 Pregnant Women ......................................................................................................... 2 Breast-feeding ..............................................................................................................
3 Pediatrics ...................................................................................................................... 4 Geriatrics ......................................................................................................................
14 8 ADVERSE REACTIONS ........................................................................................................... 1 Adverse Reaction Overview ................................................................................................
2 Clinical Trial Adverse Reactions .......................................................................................... 1 Clinical Trial Adverse Reactions – Pediatrics ................................................................
3 Less Common Clinical Trial Adverse Reactions ................................................................... 5 Post-Market Adverse Reactions ..........................................................................................
21 9 DRUG INTERACTIONS ........................................................................................................... 1 Serious Drug Interactions....................................................................................................
2 Drug Interactions Overview ................................................................................................ 3 Drug-Behavioural Interactions ............................................................................................
4 Drug-Drug Interactions ....................................................................................................... 5 Drug-Food Interactions .......................................................................................................
6 Drug-Herb Interactions ....................................................................................................... 7 Drug-Laboratory Test Interactions ......................................................................................
34 10 CLINICAL PHARMACOLOGY .................................................................................................. 1 Mechanism of Action....................................................................................................
2 Pharmacodynamics ...................................................................................................... 3 Pharmacokinetics .........................................................................................................
35 11 STORAGE, STABILITY AND DISPOSAL ..................................................................................... 36 12 SPECIAL HANDLING INSTRUCTIONS ......................................................................................
36 PART II: SCIENTIFIC INFORMATION ................................................................................................... 37 13 PHARMACEUTICAL INFORMATION .......................................................................................
37 14 CLINICAL TRIALS […]